Global Opioid Induced Constipation Treatment Market - 2022-2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	180 Pages	DataM Intelligence 4Market Research LLP	October, 2022	DTAM17463488

Best Price Guarantee
Price	from $4,350
Length	180 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	October, 2022
SKU	DTAM17463488

Global Opioid Induced Constipation Treatment Market - 2022-2029

Market Overview

Opioid-Induced Constipation Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.4% during the forecast period (2022-2029).

Opioid analgesics are prescribed to patients with acute and chronic non-cancer pain. Opioid-induced constipation (OIC) is a type of secondary illness associated with the prolonged use of opioids. Approximately 40%-80% of patients receiving opioid analgesics may experience OIC. These medications are effective because they block pain signals by attaching to receptors throughout the nervous system. These receptors are also found in bowels.

Market Dynamics

The global opioid-induced constipation treatment market growth is driven by an expanding base of OIC sufferers as a result of the increased use of opioids in the treatment of chronic pain. Also, there is a vast unmet need in the market for highly-targeted, safe, and efficient therapeutic options for OIC management.

The rise in the availability of effective OIC drugs along with the growing prevalence of chronic idiopathic pains will drive the market growth

The patients use opioid analgesics such as morphine, hydromorphone, codeine, and others as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. For instance, according to the Center for Diseases Control and Prevention November 2021, the number of OIC prescriptions increased by 153,260,450 in 2019 and 142,816,781 in 2020. Thus, the rising volume of patient pool with opioid users demands efficient medication for the OIC ailments which is likely to fuel the Opioid-Induced Constipation market over the forecast period. The geriatric population is expected to have a significant impact on the market studied as people aged above 65 are more prone to chronic diseases.

According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. Furthermore, according to the World Health Organization, by 2030, 1 out of every 6 people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will get double to reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Thus, the increasing use of opioid analgesic prescriptions along with the growing geriatric population in developed nations will drive the market growth in the forecast period.

Lack of awareness about OIC among the patients will hamper the growth of the market

However, lack of awareness about OIC among the patients considering it as a syndrome resulting in a preference for general laxatives and ongoing research activities to develop next-generation analgesics to replace opioids are likely to hamper the market growth.

COVID-19 Impact Analysis

COVID-19 impacted the global supply chain of pharmaceuticals, positively affecting the opioid-induced constipation treatment market. Opioid use at high doses and for long periods of time can impair immune system function, complicating the course of COVID-19 disease. In various stages of the COVID-19, potential suppression of parts of the immune response may be important in prevention, clinical support, and therapeutic use of medications.

Segment Analysis

The mu-opioid receptor antagonists segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The Mu-opioid receptor antagonists are expected to account for a large revenue share over the forecast period. This dominance is owing to the availability of various types of products launched by the key players that are suitable for various symptoms in the OIC and the rise in research activities in the segment.

A few of the drugs that are readily available in the market for OIC indication are Methylnaltrexone (Relistor), Naldemedine (Symproic), Naloxegol (Movantik), and Alvimopan (Entereg). Methylnaltrexone was studied and approved for patients with advanced cancer pain or other diseases, whereas Alvimopan and Naloxegol were for non-cancer patients. Thus increasing availability of Mu-opioid Receptor Antagonists anticipated the segment growth over the forecast period.

Furthermore, in February 2021, RedHill Biopharma Ltd. signed agreements with Cosmo Pharmaceuticals NV to manufacture two key products; Movantik(μ-opioid receptor antagonist), and RHB-204, currently in a Phase 3 United States study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease. These factors are driving the growth of the market in the forecast period.

Geographical Analysis

The North American region holds the largest market share of the global opioid-induced constipation treatment market

North America is expected to dominate the opioid-induced constipation market throughout the forecast period. Dominance is due to the growing prevalence of various GI disorders among geriatric patients in the United States and a steep rise in the consumption of opioids in Canada in recent years. According to the Center for Diseases Control and Prevention 2020, in the United States, the overall opioid dispensing rate in 2020 was 43.3 prescriptions per 100 people. Thus increasing number of OIC prescriptions in the United States boot the market over the forecast period.

Furthermore, according to the study titled Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancerous pain published in the Future Medicine In June 2020, Naldemedine appears to be an effective and safe first-line therapy for the treatment of opioid-induced constipation in adults with chronic noncancer pain. Thus, rising product development in the country and several clinical studies are expected to boost the market in the region.

Competitive Landscape

The opioid-induced constipation treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca plc, Mallinckrodt Pharmaceuticals, Bausch Health (Salix Pharmaceuticals), Merck & Co Inc, Shionogi & Co Ltd, GlaxoSmithKline (Theravance Biopharma Inc), Takeda Pharmaceutical, Novartis AG (Sandoz), RedHill Biopharma, Pfizer, Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the opioid-induced constipation treatment market globally. For instance, in January 2022, BioGaia Pharma reported First Patient Enrolled in the Phase II Clinical Study Evaluating BGP345A for the treatment of opioid-induced constipation (OIC-1).

AstraZeneca PLC

Overview:

The company focuses on the discovery, development, and commercialization of prescription medicines in Oncology and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. These pharmaceutical products are then manufactured, marketed, and sold.

Product Portfolio:

MOVANTIK: MOVANTIK is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids, in adults with long-lasting (chronic) pain that is not caused by active cancer.

Why Purchase the Report?
• Visualize the composition of the global opioid-induced constipation treatment market segmentation by drug class, route of administration, distribution channel, and region highlighting the key commercial assets and players.
• Identify commercial opportunities in the global opioid-induced constipation treatment market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of global opioid-induced constipation treatment market-level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global opioid-induced constipation treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 180-200 (approximate) pages.

Target Audience
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers

1. Global Opioid-Induced Constipation Treatment Market Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Global Opioid-Induced Constipation Treatment Market -Market Definition and Overview
3. Global Opioid-Induced Constipation Treatment Market – Executive Summary: 3.1. Market Snippet By Drug Class; 3.2. Market snippet By Route of administration; 3.3. Market Snippet By Distribution Channel; 3.4. Market Snippet by Region
4. Global Opioid-Induced Constipation Treatment Market-Market Dynamics: 4.1. Market Impacting Factors; 4.1.1. Drivers; 4.1.1.1. The rise in the availability of effective OIC drugs; 4.1.1.2. Rise in the Availability of Effective OIC Drugs Along with Growing Prevalence of Chronic Idiopathic Pains; 4.1.2. Restraints:; 4.1.2.1. Lack of awareness about OIC among the patients; 4.1.3. Opportunity; 4.1.4. Impact Analysis
5. Global Opioid-Induced Constipation Treatment Market – Industry Analysis: 5.1. Porter's Five Forces Analysis; 5.2. Supply Chain Analysis; 5.3. Regulatory Analysis
6. Global Opioid-Induced Constipation Treatment Market – COVID-19 Analysis: 6.1. Analysis of Covid-19 on the Market; 6.1.1. Before COVID-19 Market Scenario; 6.1.2. Present COVID-19 Market Scenario; 6.1.3. After COVID-19 or Future Scenario; 6.2. Pricing Dynamics Amid Covid-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During Pandemic; 6.5. Manufacturer’s Strategic Initiatives; 6.6. Conclusion
7. Global Opioid-Induced Constipation Treatment Market – By Drug Class: 7.1. Introduction; 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment; 7.1.2. Market Attractiveness Index, By Drug Class Segment; 7.2. Mu-Opioid Receptor Antagonists*; 7.2.1. Introduction; 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029; 7.2.3. Methylnaltrexone; 7.2.4. Naloxegol; 7.2.5. Naldemedine; 7.2.6. Others; 7.3. Chloride Channel Activators; 7.3.1. Lubiprostone; 7.3.2. Others
8. Global Opioid-Induced Constipation Treatment Market – By Route of administration: 8.1. Introduction; 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration; 8.1.2. Market Attractiveness Index, By Route of administration; 8.2. Oral*; 8.2.1. Introduction; 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029; 8.3. Parenteral
9. Global Opioid-Induced Constipation Treatment Market – By Distribution Channel: 9.1. Introduction; 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 9.1.2. Market Attractiveness Index, By Distribution Channel Segment; 9.2. Hospital Pharmacy*; 9.2.1. Introduction; 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029; 9.3. Retail Pharmacy; 9.4. Online Pharmacy; 9.5. Other
10. Global Opioid Induced Constipation Treatment Market – By Region: 10.1. Introduction; 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region; 10.1.2. Market Attractiveness Index, By Region; 10.2. North America; 10.2.1. Introduction; 10.2.2. Key Region-Specific Dynamics; 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class; 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration; 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 10.2.6.1. The U.S.; 10.2.6.2. Canada; 10.2.6.3. Mexico; 10.3. Europe; 10.3.1. Introduction; 10.3.2. Key Region-Specific Dynamics; 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class; 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration; 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 10.3.6.1. Germany; 10.3.6.2. U.K.; 10.3.6.3. France; 10.3.6.4. Italy; 10.3.6.5. Spain; 10.3.6.6. Rest of Europe; 10.4. South America; 10.4.1. Introduction; 10.4.2. Key Region-Specific Dynamics; 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class; 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration; 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 10.4.6.1. Brazil; 10.4.6.2. Argentina; 10.4.6.3. Rest of South America; 10.5. Asia Pacific; 10.5.1. Introduction; 10.5.2. Key Region-Specific Dynamics; 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class; 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration; 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 10.5.6.1. China; 10.5.6.2. India; 10.5.6.3. Japan; 10.5.6.4. Australia; 10.5.6.5. Rest of Asia Pacific; 10.6. Middle East and Africa; 10.6.1. Introduction; 10.6.2. Key Region-Specific Dynamics; 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class; 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration; 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Global Opioid Induced Constipation Treatment Market – Competitive Landscape: 11.1. Key Developments and Strategies; 11.2. Company Share Analysis; 11.3. Product Benchmarking
12. Global Opioid Induced Constipation Treatment Market - Company Profiles: 12.1. AstraZeneca plc*; 12.1.1. Company Overview; 12.1.2. Product Portfolio and Description; 12.1.3. Key Highlights; 12.1.4. Financial Overview; 12.2. Mallinckrodt Pharmaceuticals; 12.3. Bausch Heath (Salix Pharmaceuticals ); 12.4. Merck & Co Inc; 12.5. Shionogi & Co Ltd; 12.6. GlaxoSmithKline (Theravance Biopharma Inc); 12.7. Takeda Pharmaceutical; 12.8. Novartis AG (Sandoz); 12.9. Cubist Pharmaceuticals; 12.10. Pfizer, Inc.; LIST NOT EXHAUSTIVE
13. Global Opioid Induced Constipation Treatment Market – DataM: 13.1. Appendix; 13.2. About Us and Services; 13.3. Contact Us